328 related articles for article (PubMed ID: 28341561)
1. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
[TBL] [Abstract][Full Text] [Related]
2. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
Khanna R; Powe AC; Lun Y; Soska R; Feng J; Dhulipala R; Frascella M; Garcia A; Pellegrino LJ; Xu S; Brignol N; Toth MJ; Do HV; Lockhart DJ; Wustman BA; Valenzano KJ
PLoS One; 2014; 9(7):e102092. PubMed ID: 25036864
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy of a next-generation ERT in murine Pompe disease.
Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
[TBL] [Abstract][Full Text] [Related]
6. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
7. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
8. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
[TBL] [Abstract][Full Text] [Related]
13. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
[TBL] [Abstract][Full Text] [Related]
15. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
16. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
[TBL] [Abstract][Full Text] [Related]
18. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation.
Shemesh A; Wang Y; Yang Y; Yang GS; Johnson DE; Backer JM; Pessin JE; Zong H
Am J Physiol Regul Integr Comp Physiol; 2014 Nov; 307(10):R1251-9. PubMed ID: 25231351
[TBL] [Abstract][Full Text] [Related]
20. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]